Mariko Takahashi, Harrison B Chong, Siwen Zhang, Matthew J Lazarov, Stefan Harry, Michelle Maynard, Ryan White, Heather E Murrey, Brendan Hilbert, Jason R Neil, Magdy Gohar, Maolin Ge, Junbing Zhang, Benedikt R Durr, Gregory Kryukov, Chih-Chiang Tsou, Natasja Brooijmans, Aliyu Sidi Omar Alghali, Karla Rubio, Antonio Vilanueva, Drew Harrison, Ann-Sophie Koglin, Samuel Ojeda, Barbara Karakyriakou, Alexander Healy, Jonathan Assaad, Farah Makram, Inbal Rachman, Neha Khandelwal, Pei-Chieh Tien, George Popoola, Nicholas Chen, Kira Vordermark, Marianne Richter, Himani Patel, Tzu-Yi Yang, Hanna Griesshaber, Tobias Hosp, Sanne van den Ouweland, Toshiro Hara, Lily Bussema, Rui Dong, Lei Shi, Martin Q Rasmussen, Ana Carolina Domingues, Aleigha Lawless, Jacy Fang, Satoshi Yoda, Linh Phuong Nguyen, Sarah Marie Reeves, Farrah Nicole Wakefield, Adam Acker, Sarah Elizabeth Clark, Taronish Dubash, David E Fisher, Shyamala Maheswaran, Daniel A Haber, Genevieve Boland, Moshe Sade-Feldman, Russel Jenkins, Aaron Hata, Nabeel Bardeesy, Mario L Suva, Brent Martin, Brian Liau, Christopher Ott, Miguel N Rivera, Michael S Lawrence, Liron Bar-Peled
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed DrugMap , an atlas of cysteine ligandability compiled across 416 cancer cell lines. We unexpectedly find that cysteine ligandability varies across cancer cell lines, and we attribute this to differences in cellular redox states, protein conformational changes, and genetic mutations...
October 23, 2023: bioRxiv